24 May 2013
Keywords: strong, early, data, immufact, imp321, breast, cancer
Article | 03 December 2007
Orsay, France-based Immutep SA reported positive interim results from a
Phase I/II study of its lead product, ImmuFact IMP321 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 December 2007
23 May 2013
© 2013 thepharmaletter.com